XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
ORLADEYO:
U.S.$75,268 $60,106 $208,934 $162,743 
Outside of U.S.10,416 5,866 26,173 18,155 
Total ORLADEYO85,684 65,972 235,107 180,898 
Other revenues1,058 9,855 2,904 10,384 
Total revenues$86,742 $75,827 $238,011 $191,282 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues and royalties. Other revenues primarily relate to the Company’s product sales and royalties for peramivir injection (RAPIVAB/RAPIACTA/PERAMIFLU) and galidesivir development contracts with BARDA/HHS and NIAID/HHS.